• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·EAPH
Share

Parallel Industries Inc. Stocks

$ 0Last Updated 30.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 26899

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Currently, Parallel Industries Inc. does not conduct substantial business operations. Historically, the company was involved in developing and commercializing various topically applied medications to treat cancer, alongside other therapeutic solutions for a range of medical conditions. Its strategic emphasis has typically covered the entire pharmaceutical process: from development and licensing to manufacturing and marketing of both prescription and over-the-counter products. Established in 1997, the firm is headquartered in Toronto, Canada, and was formerly known as Easton Pharmaceuticals Inc. before rebranding as Parallel Industries Inc. in December 2020.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

02.11.2026 15:10

"Some People Might Get Nervous": What Lies Ahead for the Tenge and Investors in Kazakh Bonds

02.11.2026 13:46

Goldman Sachs has raised its oil price forecast for 2027. What risks does the bank see?

02.11.2026 12:19

Top Stories This Morning: Binance Customers Withdrew $3.6 Billion After the Hack; Kioxia Plummets

02.11.2026 11:34

U.S. Congressional Elections and Apple's Earnings Report: What Investors Can Expect This Week

01.11.2026 22:01

IPO roundup: Anthropic publishes prospectus, Blue Lagoon revives listing plans

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026